Two teams of University of Cambridge students in the UK have won a prestigious international competition to commercialise innovative breast cancer technology. The teams are among 10 winners of the first Breast Cancer Startup Challenge, run by US organisations The Center for Advancing Innovation (CAI), the Avon Foundation for Women, and National Cancer Institute (NCI), a part of the National Institutes of Health. The teams will receive a $5,000 award from the Avon Foundation for Women and CAI. The money will allow them to take the business to the next phase with their startups. They will also be put in touch with venture capitalists and other funding bodies who can provide more seed funding. The challenge is aimed at teams of business, legal, medical technology/scientific, engineering, and computer science students, as well as seasoned entrepreneurs. It gives them the opportunity to create strategic business plans and start new companies focused on developing and commercialising 10 inventions that the NIH deems to have high potential to benefit the treatment of breast cancer and potentially other diseases. The first team - made up of Gates Cambridge Scholar Grecia Gonzalez, Nikolaus Wenzl, Alasdair Thong, Hind Kraytem and Tim Xu - chose to focus on early stage cancer as there is no current tool in medicine which specifically addresses the distinction between early stage cancer and invasive subtypes. The requirement is for more careful and aggressive treatment planning to resolve, potentially leading to unnecessary surgery and/or chemotherapy. These early stage cancers account for 20 per cent of all breast cancer diagnoses and 25-50 per cent of these cases become invasive within 10 years. There was also a personal reason for their choice. Grecia Gonzalez’s mother died from breast cancer last year after her initial symptoms were not regarded as serious by her doctor years before. Grecia, who is doing a PhD in Biochemistry, says: “Our platform technology can access the spatial positioning of genes within a cell. The genetic information in a cell is stored in exactly the same way in every person, but certain diseases, like cancer, can cause some genes to move. “Our technology can track these early changes and more accurately assess what the cancer is doing way before other technologies currently being used can. “When my mother passed away, I was devastated. But this competition became an opportunity to channel that difficult experience into a project that will hopefully go on to have a positive impact on breast cancer treatment and peoples’ lives.” Many members of the team have a strong business background. Nikolaus Wenzl, Alasdair Thong, and Hind Kraytem are doing an MPhil in bioscience enterprise, which covers topics that parallel the competition. Tim Xu is doing an MPhil in public policy, Hind has a biomedical engineering background and has experience in working on start-ups from her involvement with
Wednesday, 22 January 2014 10:26 KATE SWEENEY SAREUM GRANTED US CANCER DRUG PATENT
Dr Tim Mitchell Cambridge UK cancer technology business Sareum has been handed a patent boost in the United States. The AIM-quoted cancer drug discovery and development specialist says the US Patent and Trademark Office has issued notification of a grant of a patent for one of the inventions associated with the CHK1 cancer programme. The patent describes compounds, developed by Sareum and Cancer Research UK funded scientists at the Institute of Cancer Research (ICR), that inhibit the function of CHK1 kinase enzymes and their potential to treat cancer. The development builds on an announcement last September that Cancer Research Technology Ltd and the ICR had licenced the CHK1 programme to the Cancer Research Technology Pioneer Fund (CPF) and that CPF, Sareum and BACIT ltd had entered into a co-development collaboration to advance the CHK1 programme into clinical trials. This particular patent provides limited territorial coverage but is part of a wider estate, including two further patent applications published in 2013, which if granted in its current form would provide broad geographical protection for the CHK1 programme currently being pursued. Sareum's CEO, Dr Tim Mitchell, said: “Consistent with the usual business of the company, the Intellectual Property estate that underpins the CHK1 programme continues to develop, protecting the asset and enhancing its commercial value.” • PHOTOGRAPH SHOWS: Dr Tim Mitchell Related Articles Cambridge teams to commercialise breast cancer technology
I assume you mean free fall as in free fall in general relativity as in an object subject to no force and being an inertial body moving along a geodesic.
Which can't really describe a share price to be honest.
Who'd HAVE thought, that's who'd HAVE thought, you'd HAVE got such a pedantic reply to such a 'thought provoking and high quality' observation, since random single quotation marks are free of charge today.
who'd of thought that sar's sp would now be priced at less than 12% of what it once stood at some 3 years ago? whilst still continuing to fall further! Imo, this just goes to prove that, if your CEO/BOD choose to ignore and belitlle their own private investors/shareholders as a concequence of a 'can't be bothered attitude' towards including them via such 'trivial things' as a democratic input/inclusion into discounted fundraisings, (whilst at the same time time pandering to Institutional Investors!), along with continuing in the mis-guided perception that a truly amateurish communications strategy is acceptable to the markets, then look no further as to why this Cos's sp is now languishing at its current level, whilst its shareholders become ever more frustrated with the 'antics' of the BOD!
Sareum's pipeline is built on the expertise of its founders in pre-clinical drug discovery, particularly in the field of cancer. Sareum operates as a "virtual" research organisation i.e. all our research is carried out in the laboratories of collaborators or third-party providers. This enables us to access drug discovery expertise throughout the world with a very flexible cost base. Sareum concentrates its research on targeted small molecule therapeutics. Targeted cancer therapies disrupt specific biochemical processes necessary for tumour growth and survival. Because these processes are specific to cancer cells, targeted therapies may be more effective than other types of treatments, such as chemotherapy and radiotherapy, and less harmful to normal cells. Small molecule therapeutics (as opposed to "biological" drugs such as antibodies) are able to penetrate into the interior of a cancer cell and thus can be targeted at the full range of processes in a biochemical pathway. Small molecule therapeutics also have the potential of being able to be administered orally (e.g. as a pill) rather than by injection.
Our strategy is to focus on developing best in class therapies where pre-clinical and early clinical data is available to indicate that disrupting the targeted biochemical process will indeed prevent tumour growth and survival without significant side-effects, and to indicate whether or not the therapy needs to be administered in combination with additional cancer therapies.
Cancer cells differ from normal cells in many different ways. In particular, cancer cells divide and grow much more rapidly than normal cells. Biochemical processes targeted by Sareum that control cell growth and division include Checkpoint Kinase 1 (Chk1), Aurora Kinase (Aurora), FMS-like Tyrosine Kinase 3 (FLT3), Anaplastic Lymphoma Kinase (ALK), Polo-Like Kinase (PLK) and B-raf. Once a solid tumour reaches a certain size, it needs to be connected to the body's blood and lymph systems to receive nutrients and remove waste. Vascular Endothelial Growth Factor Receptor 3 Kinase, (VEGFR-3, sometimes referred to as Fms-like Tyrosine Kinase 4, FLT4) is importantly involved in the generation of new blood and lymph vessels to a tumour. VEGFR-3 is also involved in the control of metastasis, which is the main cause of death in cancer patients. Many cancer cells are highly dependent on fatty acid levels of which Fatty Acid Synthase (FASN) is a key regulator.
Kinase enzymes are also involved in the control of the immune response. FMS-like Tyrosine Kinase 3 (FLT3) is implicated in the maturation of dendritic cells, implicated in multiple sclerosis, rheumatoid arthritis and other auto-immune diseases. Tyrosine Kinase 2 (TYK2) controls the JAK-STAT pathway which is over-activated in many auto-immune disorders, including rheumatoid arthritis, psoriasis and Crohn's disease.
I think it should be a requirement of site membership that people have to sign an agreement slip saying that they understand how this is calculated.
Lse simply gets the number of shares and price details from the exchange. It then has the simplest of calculations to determine its guess at whether it's a buy or sell.
Take yesterday. The quoted spread was 0.50 - 0.55 all day. Provided you dealt within the NMS, the real spread was about 0.501 - 0.522. So, using LSE's sophisticated algo programme, any trade below 0.525 was deemed a sell. Nothing sinister. Nothing manipulative by MM's.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.